TCMD Reiterated by BTIG -- Price Target Maintained at $40
BTIG has reiterated a "Buy" rating on Tactile Systems Tech (TCMD), maintaining a price target of $40.00, indicating strong analyst confidence despite the stock being identified as 34.7% overvalued by GuruFocus's GF Value™. TCMD boasts a high GF Score™ of 82/100, driven by strong financial strength and momentum, but its high P/E ratio and recent insider selling suggest investors should proceed with caution regarding its current valuation.
BTIG Research Reiterates Buy Rating for Tactile Systems Technology (NASDAQ:TCMD)
BTIG Research has reiterated a "Buy" rating for Tactile Systems Technology (NASDAQ:TCMD) and maintained a $40 price target, suggesting a potential 61% upside. Other analysts also have a "Moderate Buy" consensus with an average target of $38.60. The company recently reported mixed quarterly results, missing EPS estimates but exceeding revenue expectations, with shares trading around $24.84.
UBS Group AG Sells 168,372 Shares of Tactile Systems Technology, Inc. $TCMD
UBS Group AG significantly reduced its stake in Tactile Systems Technology ($TCMD) by selling 168,372 shares, ending with 197,715 shares valued at $5.7 million. Despite this, analyst sentiment remains positive with a "Moderate Buy" rating and a $38.60 average price target. The company also saw recent insider selling by its CEO and VP, missed EPS estimates, but exceeded revenue expectations in its latest quarter.
Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
Tactile Medical (Nasdaq: TCMD) announced its management will participate in the William Blair 46th Annual Growth Stock Conference from June 2-4, 2026, presenting on June 2nd at 9:20 a.m. Central Time. A live audio webcast will be available on the company's investor relations website. Tactile Medical is a medical technology company focused on at-home therapies for chronic conditions like lymphedema and chronic venous insufficiency.
Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
Tactile Medical (Nasdaq: TCMD), a medical technology company, announced its participation in the William Blair 46th Annual Growth Stock Conference from June 2-4, 2026. Management will present on June 2nd, with a live audio webcast available on the company's investor relations website. The company focuses on developing at-home therapies for chronic conditions like lymphedema and chronic venous insufficiency.
Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
Tactile Medical announced that its management will participate in the William Blair 46th Annual Growth Stock Conference, scheduled for June 2-4, 2026, in Chicago, IL. The company's presentation will take place on Tuesday, June 2, at 9:20 a.m. Central Time, with a live audio webcast and archived replay available on their investor relations website. Tactile Medical is a medical technology company specializing in at-home therapies for chronic conditions like lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease.
Tactile Medical to webcast William Blair conference talk June 2
Tactile Medical (Nasdaq: TCMD) announced its management will present at the William Blair 46th Annual Growth Stock Conference in Chicago from June 2-4, 2026. The presentation is scheduled for Tuesday, June 2, at 9:20 a.m. CT, and a live audio webcast and replay will be available on the company’s investor relations website. Tactile Medical specializes in at-home therapies for chronic conditions such as lymphedema and lipedema.
Tactile Systems Tech stock (US87874P1012): CFO sells $113K in shares
Tactile Systems Technology's CFO recently sold $113,403 worth of TCMD shares after the company reported stronger-than-expected Q1 earnings, with EPS of -$0.08 against an expected -$0.11 and revenue of $75.3 million. The medical device firm, which focuses on at-home therapies for chronic conditions like lymphedema, has seen its stock perform strongly, returning over 135% in the past year. Despite the insider sale, the company maintains a strong competitive position in the growing home healthcare market.
Tactile Systems CFO sells $113,403 in TCMD common stock
Tactile Systems Technology Inc.'s CFO, Elaine M. Birkemeyer, sold 4,631 shares of TCMD common stock for $113,403 on May 11, 2026, to cover taxes. Despite the insider sale, management has been actively buying back shares, showing confidence in the company. The company also reported strong Q1 2026 financial results, exceeding revenue and EPS expectations.
Tactile Systems CFO sells $113,403 in TCMD common stock
Tactile Systems Technology CFO Elaine M. Birkemeyer sold 4,631 shares of TCMD common stock for $113,403 to cover tax obligations, though management is actively buying back shares. The company recently reported strong Q1 2026 financial results, exceeding EPS and revenue expectations. The stock has seen a 138% return over the past year.
TCMD (NASDAQ: TCMD) affiliate lists 4,631 shares for resale; prior sales reported
An affiliate of Tactile Systems Technology Inc. (NASDAQ: TCMD) has filed a Form 144, listing 4,631 shares for proposed resale by Fidelity Brokerage Services LLC on May 11, 2026, stemming from restricted stock vesting on May 8, 2026. The filing also disclosed two prior sales by Elaine M. Birkemeyer: 5,518 shares sold on February 23, 2026, for $156,142.85, and 7,701 shares sold on February 24, 2026, for $222,874.64. This indicates ongoing selling activity by parties associated with the issuer.
Shareholders Will Be Pleased With The Quality of Tactile Systems Technology's (NASDAQ:TCMD) Earnings
Tactile Systems Technology (NASDAQ:TCMD) saw a positive stock price reaction following a strong earnings report. The analysis highlights that the company's statutory earnings likely understate its true potential, given its negative accrual ratio and free cash flow of US$39 million, significantly exceeding its US$20.3 million profit. Additionally, its earnings per share increased by 33% over the last year.
TACTILE SYSTEMS TECHNOLOGY (TCMD) director receives 6,521-share equity grant
TACTILE SYSTEMS TECHNOLOGY (TCMD) director Raymond Huggenberger received an equity grant of 6,521 restricted stock units, increasing his direct holdings to 62,841 shares. The grant, valued at $0.00 per share, vests fully on the earlier of one year from the grant date or the next annual stockholders' meeting, aligning his compensation with the company's long-term performance. This insider transaction was reported in an SEC Form 4 filing on May 8, 2026.
Tactile Systems Technology (TCMD) director awarded 6,521 RSUs
Tactile Systems Technology director William W. Burke was granted 6,521 restricted stock units (RSUs) of Common Stock, which will vest on the earlier of one year from the grant date or the next annual stockholders' meeting. This award increases his direct holdings to 55,041 shares. The transaction, reported on a Form 4 SEC filing, is categorized as a grant/award acquisition, not an open-market purchase, and is considered neutral in terms of filing sentiment and impact.
[Form 4] TACTILE SYSTEMS TECHNOLOGY INC Insider Trading Activity
Tactile Systems Technology director David Brent Shafer received an equity award of 6,521 restricted stock units, as detailed in a Form 4 SEC filing. These shares were granted at a price of $0.00 and will vest fully on the earlier of one year from the grant date or the next annual stockholders' meeting. After this transaction, Shafer directly holds 55,343 common shares in the company.
Carmen Volkart (TCMD) receives 6,521 restricted stock units as award
Carmen B. Volkart, a director at Tactile Systems Technology Inc. (TCMD), was granted 6,521 restricted stock units (RSUs) on May 6, 2026, as part of her compensation, with no purchase price. These RSUs will fully vest either one year from the grant date or by the next annual shareholders' meeting. Following this award, Ms. Volkart directly holds a total of 44,219 shares in the company.
[Form 4] TACTILE SYSTEMS TECHNOLOGY INC Insider Trading Activity
Tactile Systems Technology Inc. director Laura G. King received an equity award of 6,521 shares of Common Stock in the form of restricted stock units (RSUs) with a grant price of $0.00 per share. This non-cash compensation increases her direct holdings to 25,569 shares. The RSUs will vest in full on the earlier of one year from the grant date or the next annual stockholders' meeting, aligning her interests with continued board service.
[Form 4] TACTILE SYSTEMS TECHNOLOGY INC Insider Trading Activity
TACTILE SYSTEMS TECHNOLOGY INC director Valerie L. Asbury reported an acquisition of 6,521 shares of common stock as a restricted stock unit grant, which will vest on the earlier of one year from the grant date or the next annual meeting of stockholders. This transaction increases her direct holdings to 55,343 shares, with a grant price of $0.00 per share. The filing highlights key details of the grant and her subsequent ownership.
Tactile Systems Tech stock (US87874P1012): Q1 2026 sales up 23% on Medicare headwinds
Tactile Systems Technology (TCMD) reported a 23% year-over-year increase in Q1 2026 revenue, reaching $75.3 million, despite facing new Medicare prior-authorization requirements. The company's core business revolves around home-based compression therapy devices for chronic conditions, with its Flexitouch system being the primary revenue driver. While growth was attributed to strategic execution and commercial momentum, the stock remains volatile due to investor uncertainty regarding reimbursement policies and the sustainability of its turnaround.
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Consensus Rating of "Moderate Buy" from Analysts
Tactile Systems Technology, Inc. (NASDAQ:TCMD) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $38.60. Despite missing EPS estimates, the company exceeded revenue expectations in its latest quarter. Insider selling was observed, but institutional ownership remains high, with several major funds increasing or establishing positions.
Tactile Systems (NASDAQ: TCMD) holders re-elect board and approve charter change
Tactile Systems Technology, Inc. shareholders re-elected all nine director nominees with strong support and ratified Grant Thornton LLP as their independent auditor for 2026. They also approved executive compensation on an advisory basis and passed a charter amendment to align director removal procedures with Delaware law. This indicates broad confidence in the company's governance and strategic direction.
Earnings call transcript: Tactile Systems Q1 2026 shows strong growth
Tactile Systems (TCMD) reported a strong Q1 2026, exceeding revenue and EPS forecasts with a 23% year-over-year revenue growth. The company achieved an EPS of -$0.08 against an expected -$0.11 and revenue of $75.3 million, surpassing the $68.45 million forecast. Following the announcement, the stock saw a positive market reaction, climbing over 7% in after-hours and premarket trading, and the company updated its full-year 2026 revenue guidance to $360 million-$368 million.
Tactile Systems Technology (NasdaqGM:TCMD) Stock Forecast & Analyst Predictions
Tactile Systems Technology (NasdaqGM:TCMD) is predicted to see significant growth, with earnings and revenue forecast to increase by 29% and 8.4% per annum, respectively. Analyst price targets have generally been lifted, reflecting optimism around recent Q4 performance, updated guidance, and productivity improvements, especially in the lymphedema business. The company has also announced several updates regarding earnings guidance, product launches (Nimbl), and board appointments, alongside details of share repurchase programs.
Tactile Medical (NASDAQ: TCMD) lifts 2026 outlook after strong Q1 growth
Tactile Medical reported strong Q1 2026 results with a 23% increase in total revenue to $75.3 million, driven by growth in both lymphedema and airway clearance products. The company also saw significant improvements in profitability, including a narrowed operating loss and positive Adjusted EBITDA. Based on this performance, Tactile Medical raised its full-year 2026 revenue outlook to $360–$368 million and reaffirmed its Adjusted EBITDA guidance of $49–$51 million.
Tactile Systems Technology (NASDAQ:TCMD) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS
Tactile Systems Technology (NASDAQ:TCMD) reported its quarterly earnings, announcing an EPS of ($0.08), which missed the consensus estimate by $0.01. Despite the EPS miss, the company's revenue of $75.27 million exceeded analyst predictions of $70.57 million. Following the announcement, shares fell to $22.43 on heavy volume, trading below their 50- and 200-day moving averages, while analysts maintain a "Moderate Buy" rating with an average price target of $37.40.
BTIG Research Issues Positive Forecast for Tactile Systems Technology (NASDAQ:TCMD) Stock Price
BTIG Research has increased its price target for Tactile Systems Technology (NASDAQ:TCMD) stock from $38.00 to $40.00, maintaining a "buy" rating and suggesting a potential upside of 78.33%. Despite an EPS miss, the company's revenue exceeded expectations, and while insiders have been selling shares, institutional investors hold a significant stake. Analysts have a "Moderate Buy" consensus rating with a target price of $37.80 for the medical device company.
Tactile Medical projects $360M-$368M 2026 revenue as Medicare prior authorization process matures
Tactile Medical (TCMD) is projecting its 2026 revenue to be between $360 million and $368 million. This outlook is based on the assumption that Medicare's prior authorization process will mature and stabilize, influencing the company's financial performance.
Precision Trading with Tactile Systems Technology Inc. (TCMD) Risk Zones
This article provides an in-depth analysis of Tactile Systems Technology Inc. (TCMD) focusing on its sentiment, risk parameters, and AI-generated trading strategies. It highlights weak near and mid-term sentiment but a strong long-term outlook, offering specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies. The analysis is based on multi-timeframe signals to aid precision trading decisions.
Full Transcript: Tactile Systems Tech Q1 2026 Earnings Call - Tactile Systems Tech (NASDAQ:TCMD)
Tactile Systems Tech (NASDAQ:TCMD) reported strong Q1 2026 results with a 23% revenue increase to $75.3 million and improved gross margins to 76.5%, leading to a raised full-year revenue guidance of $360-$368 million. The company highlighted successful operational execution, strategic investments in AI for Medicare prior authorization, and confidence in long-term growth drivers like the Lymphotek acquisition and the launch of next-generation AfloVest. Management addressed early variability in Medicare prior authorization processes, expressing confidence in their ability to navigate these administrative challenges.
Earnings call transcript: Tactile Systems Q1 2026 beats expectations
Tactile Systems Technology Inc. (TCMD) significantly beat Q1 2026 earnings and revenue expectations, reporting an EPS of -$0.08 against an anticipated -$0.11 and revenue of $75.3 million compared to a forecasted $68.45 million, a 23% year-over-year revenue increase. Despite the strong financial performance and raised full-year revenue guidance, the stock saw a slight aftermarket decline of 0.17%, closing at $22.85, reflecting cautious investor sentiment due to ongoing net losses and increased operating expenses. The company emphasized strategic investments in operational efficiency, product innovation, and market expansion, including the acquisition of LymphaTech and the upcoming launch of a next-generation AffloVest.
Tactile Systems Technology (NASDAQ:TCMD) Q1 2026 Revenue Beat Fails to Offset EPS Miss, Stock Falls 5%
Tactile Systems Technology (NASDAQ:TCMD) reported mixed Q1 2026 results, with revenue of $75.3 million beating analyst estimates but a Non-GAAP EPS of -$0.08 missing expectations. Despite the revenue beat, the stock fell about 5.2% in after-hours trading due to the larger-than-expected loss per share and the company's silence on forward guidance. This further extended recent share price weakness, highlighting investor concerns about ongoing profitability challenges in a competitive market.
Tactile Medical gets FDA clearance for new airway vest as revenue hits $75M
Tactile Medical (TCMD) announced strong Q1 2026 financial results, with total revenue increasing 23% year-over-year to $75.3 million and Adjusted EBITDA turning positive at $3.7 million. The company also received FDA 510(k) clearance for its next-generation AffloVest airway clearance device, acquired LymphaTech to expand its lymphedema solutions, and updated its full-year 2026 revenue guidance to $360 million to $368 million. These developments highlight the company's operational strength, strategic growth initiatives, and expanding product portfolio.
BRIEF-Tactile Systems Technology Q1 Revenue USD 75.3 Million Vs. IBES Estimate USD 70.6 Million
Tactile Systems Technology reported its Q1 revenue reached USD 75.3 million, surpassing the IBES estimate of USD 70.6 million. This brief financial update indicates stronger-than-expected performance for the company in the first quarter.
Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results
Tactile Systems Technology, Inc. (TCMD) reported a strong start to 2026 with a 23% year-over-year increase in total revenue to $75.3 million for the first quarter, driven by growth in both lymphedema and airway clearance product lines. The company also saw an expansion in gross margin to 76.5% and achieved a positive Adjusted EBITDA of $3.7 million, compared to a loss in the prior year. Tactile Medical updated its full-year 2026 revenue guidance to a range of $360 million to $368 million, representing 9% to 12% growth.
Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates
Tactile Systems Technology (TCMD) reported a Q1 loss of $0.08 per share, exceeding the Zacks Consensus Estimate of a $0.07 loss, but topped revenue estimates with $75.27 million. The company's shares have declined 21.1% year-to-date, contrasting with the S&P 500's gain, and currently hold a Zacks Rank #3 (Hold). Investors are now looking at the company's future earnings outlook and management commentary for guidance on the stock's direction.
Tactile Systems Technology (Nasdaq:TCMD) - Stock Analysis
Tactile Systems Technology (TCMD) is a medical technology company specializing in devices for chronic diseases, particularly lymphedema. The stock is considered significantly undervalued by analysts, trading 46.9% below its estimated fair value. Recent analyst updates show a consolidated price target of $38, driven by strong Q4 execution, positive multi-year guidance, and ongoing improvements in revenue growth and profit margins.
Tactile Systems Technology (TCMD) Expected to Announce Quarterly Earnings on Monday
Tactile Systems Technology (NASDAQ:TCMD) is expected to announce its Q1 2026 earnings on Monday, May 4th, with analysts projecting an EPS of ($0.07) and revenue of approximately $70.57 million. The company's prior quarter results beat expectations, and analysts forecast a $1.00 EPS for the current and next fiscal years. Insider selling has been observed, while institutional investors hold a significant portion of the stock, and the analyst consensus is a "Moderate Buy."
Tactile Systems Technology (NASDAQ:TCMD) Stock Passes Below 50 Day Moving Average - Should You Sell?
Tactile Systems Technology's stock (NASDAQ:TCMD) recently fell below its 50-day moving average, trading at $24.96 against an average of $26.94. Despite beating earnings expectations and receiving a "Moderate Buy" consensus rating with an average target of $37.40 from analysts, insiders have sold a significant number of shares, though institutional ownership remains high at over 83%. The article suggests reviewing key financial metrics and analyst opinions before making investment decisions.
Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026
Tactile Medical announced it will release its first-quarter fiscal year 2026 financial results after market close on Monday, May 4, 2026. Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the results, with participation details provided for both live access and replay. The call will also be webcast and archived on the company's investor relations website.
Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026
Tactile Medical announced that its first-quarter fiscal year 2026 financial results will be released on Monday, May 4, 2026, after market close. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the results. Replays of the call will be available for two weeks.
Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026
Tactile Systems Technology, Inc. (Tactile Medical) announced it will release its first-quarter fiscal year 2026 financial results after market close on Monday, May 4, 2026. The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss these results, with replay and archive options available for those unable to participate live.
Tactile Medical sets May 4 Q1 results release, 5 p.m. ET call
Tactile Medical (Nasdaq: TCMD) announced it will release its first quarter fiscal year 2026 financial results after market close on May 4, 2026. Management will host a conference call and webcast at 5:00 p.m. ET the same day to discuss the results. The announcement follows the company's established pattern of pre-announcing earnings dates for investor planning.
Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026
Tactile Medical, a medical technology company, announced it will release its first-quarter fiscal year 2026 financial results after market close on Monday, May 4, 2026. Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the results, with participation details provided for both live and replay options. The company specializes in developing and marketing at-home therapies for chronic conditions like lymphedema and lipedema.
Should You Think About Buying Tactile Systems Technology, Inc. (NASDAQ:TCMD) Now?
Tactile Systems Technology (NASDAQ:TCMD) appears to be undervalued according to Simply Wall St's valuation model, with an intrinsic value of $41.84 compared to its current trading price of $25.73. The company also shows a strong future outlook, with profits expected to more than double in the next couple of years, suggesting potential for higher cash flow and share valuation. Investors are encouraged to consider these factors, along with capital structure and management's track record, before making investment decisions.
Tactile Systems Tech stock (US87874P1012): Is lymphedema device growth strong enough to unlock new u
This article examines Tactile Systems Technology Inc. (US87874P1012), focusing on its home-based medical devices for lymphedema and chronic venous insufficiency. It analyzes the company's recurring revenue business model driven by consumables, its significant market opportunity in the underserved U.S. lymphedema market, and its potential for global expansion. The report also covers analyst views, key risks like Medicare reimbursement dependency, and future catalysts such as product pipeline updates and international pilot results.
Tactile Systems Tech stock (US87874P1012): Why lymphedema device leadership now matters more for inv
Tactile Systems Tech focuses on at-home lymphedema and chronic venous insufficiency therapies, positioning it well within the growing chronic disease market. The company's business model relies on pneumatic compression devices like the Flexitouch system, providing recurring revenue through supplies and leveraging Medicare reimbursement for home-based care. Investors should monitor evolving healthcare policies and competitive pressures, but the company's niche focus and clinical evidence provide a strong market position.
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Consensus Rating of "Moderate Buy" from Brokerages
Tactile Systems Technology (NASDAQ:TCMD) has received a consensus rating of "Moderate Buy" from seven brokerages, with an average 12-month price target of $37.40. The company recently surpassed earnings and revenue expectations, reporting $0.46 EPS against an expected $0.44, and $103.6 million in revenue compared to an estimated $93.8 million. Despite net insider selling, institutional investors maintain a significant ownership stake of approximately 83.43% in the medical device company.
Trading the Move, Not the Narrative: (TCMD) Edition
This article analyzes Tactile Systems Technology Inc. (TCMD) using AI models, highlighting weak near and mid-term sentiment despite a long-term positive outlook. It provides specific trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with entry, target, and stop-loss levels, and details multi-timeframe signal analysis for support and resistance levels. The analysis aims to guide traders based on market movements rather than prevailing narratives.
Press Releases about Tactile Systems Technology, Inc. - Common Stock (Nasdaq:TCMD)
This article compiles various press releases related to Tactile Systems Technology, Inc. (TCMD), including news about its stock performance, analyst ratings for medical device companies, executive appointments at LifeLens Technologies, and conference announcements by Sidoti & Company. It also features several reports from Kahn Swick & Foti, LLC, detailing ongoing investigations into the officers and directors of Tactile Systems Technology. The listed press releases range from 2021 to 2024, providing a historical overview of company and industry news relevant to TCMD.
How The Story Is Shifting For Tactile Systems Technology (TCMD) After Q4 And 2026 Guidance
Tactile Systems Technology (TCMD) has maintained its fair value estimate at US$38.00 after its Q4 results and 2026 guidance, reflecting a consistent view of its upside potential despite varying analyst opinions. Bullish analysts from Lake Street, BTIG, and Piper Sandler raised their targets due to strong Q4 performance, productivity improvements, and increased FY2026 revenue guidance. Conversely, B. Riley maintained a "Neutral" stance, suggesting the current share price already incorporates these positives, limiting further upside for new buyers.
